The tweet was deleted by the author.
But we saved everything 🙂.
Esperion Therapeutics estimates the annual economic burden of heart failure in the U.S. at 46 billion dollars, encompassing healthcare services, medications, and lost productivity.
The company asserts that implementing optimized guideline-directed therapy and improving patient education can lead to significant savings and better health outcomes. Esperion Therapeutics positions these measures as both cost-saving and life-saving, pointing to the dual value for the healthcare system and society.
Esperion Therapeutics has previously highlighted the 2026 ACC/AHA guidelines for dyslipidemia management, featuring insights from leading experts in an earlier announcement. The company is also scheduled to report its first quarter 2026 financial results on May 7 according to its outlined earnings calendar. These updates follow the firm's ongoing efforts to address cardiovascular health and related economic impacts.